Future Medicine Co Ltd

Future Medicine Co Ltd exhibits a highly leveraged capital structure, with total liabilities of KRW 421.5 billion and total equity of -KRW 354.0 billion, resulting in a negative debt-to-equity ratio of -0.9. The company's liquidity position is weak, as evidenced by a current ratio of 0.08 and negative free cash flow of -KRW 140.7 billion. Cash and equivalents of KRW 212.5 billion are insufficient to cover long-term debt of KRW 316.9 billion, indicating a high reliance on external financing. Profitability metrics are severely negative, with a return on assets of -2.42 and a return on equity of 0.461. These figures fall well below the typical thresholds for pharmaceutical companies, which usually require positive ROE and ROA to sustain operations and R&D investments. The company's operating and net losses of -KRW 1.64 billion and -KRW 1.63 billion, respectively, underscore its inability to generate earnings from core operations. The company's revenue is reported as zero, suggesting either a reporting anomaly or a complete absence of revenue-generating activities in the latest period. Given the lack of revenue data, it is impossible to assess geographic or segment concentration. However, the company's disclosed focus on synthetic drug development implies a high concentration in R&D-driven operations, with limited diversification across therapeutic areas or geographies. The company's growth trajectory is unclear due to the absence of revenue data and the presence of significant operating losses. The outlook for the current and next fiscal years is not quantifiable without additional data on revenue trends or strategic initiatives. The company's financial performance suggests a high risk of insolvency or restructuring in the near term. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position, driven by long-term debt exceeding cash reserves, increases its vulnerability to liquidity shocks. However, the low dilution risk suggests that the company is not currently issuing shares at a rate that would significantly dilute existing shareholders. Recent filings and transcripts are not available in the provided data, so no specific events can be cited. However, the company's financial snapshot indicates a deteriorating financial position, with negative operating and net income, and a negative equity position. These factors suggest a need for close monitoring of the company's capital structure and liquidity management.